- Home
- GUG vs LRMR Comparison
GUG vs LRMR Comparison
Compare GUG & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUG
- LRMR
- Stock Information
- Founded
- GUG 2021
- LRMR N/A
- Country
- GUG United States
- LRMR United States
- Employees
- GUG N/A
- LRMR N/A
- Industry
- GUG Trusts Except Educational Religious and Charitable
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- GUG Finance
- LRMR Health Care
- Exchange
- GUG Nasdaq
- LRMR Nasdaq
- Market Cap
- GUG 493.4M
- LRMR 426.9M
- IPO Year
- GUG N/A
- LRMR N/A
- Fundamental
- Price
- GUG $15.05
- LRMR $4.00
- Analyst Decision
- GUG
- LRMR Strong Buy
- Analyst Count
- GUG 0
- LRMR 8
- Target Price
- GUG N/A
- LRMR $19.63
- AVG Volume (30 Days)
- GUG 108.9K
- LRMR 1.1M
- Earning Date
- GUG 01-01-0001
- LRMR 10-30-2024
- Dividend Yield
- GUG 9.67%
- LRMR N/A
- EPS Growth
- GUG N/A
- LRMR N/A
- EPS
- GUG N/A
- LRMR N/A
- Revenue
- GUG N/A
- LRMR N/A
- Revenue This Year
- GUG N/A
- LRMR N/A
- Revenue Next Year
- GUG N/A
- LRMR N/A
- P/E Ratio
- GUG N/A
- LRMR N/A
- Revenue Growth
- GUG N/A
- LRMR N/A
- 52 Week Low
- GUG $12.71
- LRMR $3.01
- 52 Week High
- GUG $15.06
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- GUG 33.24
- LRMR 28.32
- Support Level
- GUG $14.90
- LRMR $3.83
- Resistance Level
- GUG $15.28
- LRMR $6.91
- Average True Range (ATR)
- GUG 0.28
- LRMR 0.57
- MACD
- GUG -0.04
- LRMR -0.16
- Stochastic Oscillator
- GUG 16.29
- LRMR 25.26
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.